secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001549084-23-000008
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics reports FY 2022 revenue up 15% to $12.9M, net loss widens to $15.1M
--------------------------------------------------------------------------------

- Full-year revenue $12.9M (up 15% YoY); Q4 revenue $3.6M vs $4.1M year ago.
- Net loss $15.1M ($1.16 per share) for FY2022, vs $9.8M loss ($0.80 per share) in 2021.
- Gross margin declined to 48% from 60% due to higher service, supply chain, and labor costs.
- Cash at Dec 31, 2022 was $20.5M, down from $40.4M; operations used $14.7M cash.
- Completed acquisition of Parker Hannifin's HMC business (Indego product line); FDA clearance for EksoNR in MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/0001549084-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000154908423000008/ekso-20230328.htm
  HTML page:      https://secwatch.observer/filing/0001549084-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer